Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
While Sutro shows why it’s shelved luvelta-T.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
The acquisition of Araris follows a 2023 discovery collaboration.
The company buys Belgium’s EsoBiotec for $425m.
At long last luvelta-T is shelved, and Sutro seeks a new focus.
The Japanese group licenses sapablursen from Ionis for $280m.
